phlebitis. Vascular complications following infusion, transfusion and therapeutic injection
Conditions
Interventions
Intervention 1: Use of Placebo (cream base) in the control group for 72 hours in 12-hour intervals in the area of phlebitis. Intervention 2: Use of Tannic acid 7% in intervation group for 72 hours i
Placebo
Treatment - Drugs
Use of Placebo (cream base) in the control group for 72 hours in 12-hour intervals in the area of phlebitis
Use of Tannic acid 7% in intervation group for 72 hours in 12-hour intervals in the area of phlebitis
Use of Quercetin 2% in intervation group for 72 hours in 12-hour intervals in the area of phlebitis
Use the combination of Quercetin 2% and Tannic acid %7 in an intervention group for 72 hours in 12-hour intervals in the area of phlebitis
Sponsors
Deputy of Research and Technology, Birjand University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: IInclusion criteria: having an IV catheter, gauge No. 20 (with all catheters of an essentially single brand), age between 18-60 years old, hospitalization in the internal medicine ward for at least 72 hours, no allergy to the drugs and the wound dressing, lack of blood transfusion, systolic blood pressure between 90 to 180 mmHg, no diabetes, no skin disease in the area of phlebitis, no pregnancy or lactation, having at least one phlebitis symptom (pain, redness, irritation) around the area, no chemical or herbal oil use for treatment of the phlebitis during the study, no history of allergy to the plants containing Quercetin or Tannic acid, using upper limbs for catheterization, using aseptic conditions for catheterization Exclusion criteria: patients discharged before three days, taking contraceptive drugs, patients with known comorbidities including hyper-coagulability states (e.g., anti-cardiolipin antibodies, anti-phospholipid antibodies, and vitamin C deficiency)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phlebitis. Timepoint: Before and 12 hours after treatment for 72 hours. Method of measurement: 4 degree visual phlebitis scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Dermal side effects. Timepoint: 12 hours for 72 hours. Method of measurement: Observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohsen Foadoddini
Birjand University of Medical Sciences
Outcome results
None listed